Furthermore, OS by KM analysis revealed that FDX1 was a risk factor for patients with adrenocortical carcinoma (ACC), HNSC, LGG, and pancreatic adenocarcinoma (PAAD) and was a protective factor for patients with COAD, KIRC, and SKCM (Figures 3B–H). Here, FDX1 is linked to pancreatic adenocarcinoma.